Dowling touched on this slightly in the call. I think he said the current top players only account for 17% of the market, and the market will grow with FDA guidance while the competition will contract almost overnight, leaving 83% up for grabs theoretically with the existing good actors in the market. A vacuum that will need immediate filling.
Even if there are 10 larger companies that enter the space there should be a brief period CVSI can capitalize before others do by being on store shelves already with other products. And even once they enter if CVSI can maintain even 5% of the market that's a big number. If Brightfield is correct at the market gets to $15B, 5% is $750m, 1% is $150m.
IMO if CVSI gets in at Walmart or the like they've made their day. Everything else is gravy.